Source:http://linkedlifedata.com/resource/pubmed/id/15013028
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2004-3-11
|
| pubmed:abstractText |
In the present study we investigated the effects of co-administration of GM(1) (15.0 mg/kg, twice daily, for 30 days) and haloperidol (1.0 mg/kg, twice daily, for 30 days), as well as the effects of a 5-day treatment with this dose of GM(1) after withdrawal from haloperidol in rats. The animals were evaluated in the open-field test and apomorphine-induced stereotyped behaviour. The results show that GM(1) was able to attenuate dopaminergic supersensitivity evaluated by the locomotion frequency at 24 and 48 h after the withdrawal from haloperidol. On the other hand, rearing frequency was changed neither by haloperidol nor by GM(1.) In haloperidol-treated rats immobility time differs from 30 min observation session in comparison with the following sessions after the withdrawal from neuroleptic. Apomorphine-induced stereotyped behaviour produced a significant increase in scores of haloperidol-withdrawn rats. GM(1) did not modify the haloperidol effects and did not change the dopamine receptor affinity to apomorphine 100 h from abrupt neuroleptic withdrawal.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Apomorphine,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/G(M1) Ganglioside,
http://linkedlifedata.com/resource/pubmed/chemical/Haloperidol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0924-977X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
127-33
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15013028-Analysis of Variance,
pubmed-meshheading:15013028-Animals,
pubmed-meshheading:15013028-Apomorphine,
pubmed-meshheading:15013028-Behavior, Animal,
pubmed-meshheading:15013028-Dopamine Agonists,
pubmed-meshheading:15013028-Dopamine Antagonists,
pubmed-meshheading:15013028-Drug Administration Schedule,
pubmed-meshheading:15013028-Drug Interactions,
pubmed-meshheading:15013028-G(M1) Ganglioside,
pubmed-meshheading:15013028-Haloperidol,
pubmed-meshheading:15013028-Immobilization,
pubmed-meshheading:15013028-Locomotion,
pubmed-meshheading:15013028-Male,
pubmed-meshheading:15013028-Rats,
pubmed-meshheading:15013028-Rats, Wistar,
pubmed-meshheading:15013028-Stereotyped Behavior,
pubmed-meshheading:15013028-Substance Withdrawal Syndrome,
pubmed-meshheading:15013028-Time Factors
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats.
|
| pubmed:affiliation |
Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|